Galectin-9 (Gal-9) is a tandem repeat-type member of the galectin family and is a ligand for T-cell immunoglobulin mucin domain 3 (Tim-3), a type-I glycoprotein that is persistently expressed on dysfunctional T cells during chronic infection.
Introduction
Prophylactic interventions against HIV-1 acquisition, such as vaccine and microbicide candidates, have not proved efficacious or have even enhanced acquisition in previous human clinical trials 1, 2 . Even the most promising vaccine to date, which involved a canarypox prime followed by a gp120 protein boost, only showed limited efficacy that waned over time 3 . More effective strategies that block initial HIV-1 acquisition at the site of exposure are required.
Interestingly, deletion of 32 base pairs in the ccr5 gene 4 and selective upregulation of p21 in CD4 + T cells from elite controllers 5 render some individuals naturally resistant to HIV-1 infection. The mechanism(s) responsible for resistance of CD4 + T cells to HIV-1 infection are not well known, but defining them is vital for designing prophylactic interventions.
Galectin-9 (Gal-9), a member of the β -galactoside-binding animal lectin family, was originally characterized as an eosinophil chemoattractant 6 .
Subsequent studies determined that it is a versatile immunomodulator involved in a wide range of biological activities such as cell adhesion and migration, proliferation and apoptosis, interaction of host cells with microbial pathogens, regulatory T cell (Treg) differentiation and function, dendritic cell maturation and antimicrobial immunity [7] [8] [9] [10] [11] [12] [13] . Gal-9 is expressed by eosinophils, endothelial cells, T lymphocytes, dendritic cells, macrophages, lymphoid cells, kupffer cells, intestinal epithelial cells and vascular endothelial cells 10, [14] [15] [16] [17] [18] [19] . Wide distribution of Gal-9 on host cells demonstrates an important but complex role for this lectin, whose biological effects are exerted by two receptors with distinct, and often Although, the Tim-3:Gal-9 interaction in autoimmunity and tolerance induction has been extensively studied, the role of this receptor:ligand interaction in antiviral immunity has not been fully elucidated. Data suggest that Tim-3:Gal-9
interactions in the context of microbial infection leads to a dual outcome, either enhancement of innate immunity and clearance of pathogen 10 or termination of adaptive immunity and reduction in inflammation-related tissue damage 26 . This
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From may be related to the fact that Tim-3 ligation on dendritic cells and macrophages leads to their activation, whereas Tim-3 ligation on T cells results in their inhibition 13 . Although many Gal-9 functions, in particular on T-cells, are regulated via Tim-3 binding, various Tim-3-independent effects of Gal-9 have been reported 27 . These observations indicate that the effects of Gal-9 on T cells are mediated by additional receptors apart from Tim-3.
A recent study revealed the cell surface protein disulfide isomerase (PDI) as a novel T cell glycoprotein receptor for Gal-9, and demonstrated that the Gal-9:PDI interaction enhanced HIV-1 entry and infection in CD4 + T cells
21
. As a result interaction of Gal-9 with different receptors can have either positive or negative effects on different cell types or the same cell type in different inflammatory settings.
In the present study, we demonstrate a novel role for Tim-3 in the context of HIV-1 infection and show that Gal-9:Tim-3 interactions reduce HIV-1 infection in activated CD4 + T cells. The mechanisms by which Gal-9 acted in vitro are likely complex and involve down-regulation of HIV-1 co-receptors such as CXCR4, CCR-5 and α4β7, and up-regulation of p21 (Waf1/Cip1) in CD4 + T cells, which has been reported to be associated with control of HIV-1 replication 5 . Therefore, our data suggest that Gal-9:Tim-3 interactions are beneficial in the context of 
Materials and Methods

Study Population
PBMC samples from 12 HIV-and 4 HIV+ individuals were used for this study.
Plasma samples for Gal-9 detection were obtained from 30 chronically HIV+ individuals. The appropriate Institutional Review Boards at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle BioMed approved the studies. All study participants gave written informed consent to participate in this study in accordance with the Declaration of Helsinki.
HIV-1 Viruses
The CXCR4-utilizing isolate LAI and the CCR5-utilizing HIV-1 strain CSF-Jr were 
Ex vivo Infection Assays
CD4
+ T cells were cultured in RPMI supplemented with 10% fetal bovine serum, recombinant IL-2 (50 U/ml), and PHA (2 μg/ml). After 3 days, cells were washed and treated with different concentrations of stable Gal-9 (sGal-9 or G9NC(null) (provided by GalPharma Co., Ltd) 28 for 1-2 hr prior to infection with HIV-1. Gal-9-treated cells and untreated cells were infected with HIV-1 viruses at multiplicity of infection (MOI) of 0.1 by using magnetofection 29 . However, in some experiments, CD4 + T cells were infected first, washed extensively and then Gal-9
was added into the wells for 2 hr. Every other day, one-half of the culture For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From supernatant was replaced with fresh medium supplemented with 50 U/ml IL-2.
Four to five days post infection CD4
+ T cells were subjected to flow cytometric p24 analysis using KC57-PE anti-p24 antibody (Beckman Coulter). Parallel cultures of CD4 + T cells infected with the virus in the absence of Gal-9 served as negative controls.
Blocking Assays
PHA stimulated CD4 + T cells were incubated with 2.5-10 μg/ml anti-Tim-3 polyclonal antibody or immunoglobulin G (IgG) isotype control (R&D Systems) or 10 μg/ml LEAF anti-Tim-3 (clone F38-2E2, BioLegend) at 37°C for +30 hr to block the interactions of Tim-3 with Gal-9. In addition, in some other assays anti-PDI mAb (clones RL77, RL90) from Novus Biologicals (1:3000) was used to block the interactions of PDI and Gal-9.
Cell Separation and Flow Cytometry
CD4
+ T cells were isolated by negative selection using a magnetic separation system (STEMCELL Technology). Purity was assessed as > 97% by flow cytometry using a LSRII cytometer (BD Biosciences 
RT-PCR Assays
Expression of CDKN1A and p53 mRNA were analyzed by RT-PCR using standard methods 5 . Total RNA was extracted from CD4 + T cells using RNeasy
Mini kit (Qiagen) RNA isolation system followed by one step RT-PCR using 
Gal-9 detection by ELISA
The Gal-9 concentration in plasma, as previously described , was quantified by ELISA (Galpharma Co. Ltd, Japan).
Results
For personal use only. Figure 2) . . Gal-9 (1 μg/ml) significantly down regulated surface expression of CXCR4 about 25% and 50% at 2 and 12 h incubation when compared with untreated cultures (P=0.037 and P=0.03 respectively; Figure   2B ,E). The inhibitory effects of Gal-9 on CXCR4 expression were significantly higher following 12 hr incubation (P=0.029; Figure 2B ). α4β7 demarcates a highly susceptible subset of CD4 + T cells
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. We cultured CD4 + T cells in the presence of retinoic acid for 3 days to express α4β7 35 ( Figure 2F ) before culturing in the presence or absence of Gal-9 (1 μg/ml). The presence of Gal-9 resulted in a significant decline in α4β7 surface expression (an average of 30% in 2 h and > 50% after in12 h incubation) when compared with untreated cultures (P=0.0049 and P=0.004 respectively; Figure 2C ,F). The suppressive effects of Gal-9 on α4β7 expression were significantly more evident when CD4 + T cells remained in the presence of Gal-9 for 12 hr (P=0.043; Figure 2C ). These data collectively indicated that Gal-9 significantly reduces surface expression of CCR5, CXCR4 and α4β7 on activated CD4 + T cells in a time dependent manner and suggested that down regulation of HIV-1 co-receptors could be a mechanism by which Gal-9 reduces HIV-1 infection in CD4 + T cells. However, many of these markers (e.g. CCR5 and α4β7) are also activation markers
, and thus the effects of Gal-9 on surface expression could simply be a result of the ability of 
Gal-9 reduces HIV-1 infection in already infected CD4 + T cells
In the previous experiments Gal-9 was added prior to HIV-1 infection of activated target cells. To determine if Gal-9 could limit HIV-1 infection in cells that were already infected, CD4 + T cells were incubated with Gal-9 for 2 hrs post-infection with HIV-1. Surprisingly, Gal-9 significantly reduced viral infectivity ≥ 75% by both X4-tropic and R5-tropic viral isolates (P=0.014 and P=0.012 respectively; Figure   3A ,B,C). Furthermore, to dissect whether the activation status of CD4 + T cells or downstream infection-related changes in cytokine milieu were responsible for the observed effects of Gal-9, cells were infected by a GFP-labeled single-cycle virus pre or post treatment with Gal-9 (0.5 μg/ml 2 hr). Gal-9 reduced viral infection with this single-cycle virus suggesting that the suppressive effects of Gal-9 are directly due to reducing susceptibility of the target cell rather than from altering downstream infection-related events ( Figure 3D ). These data demonstrated that Gal-9 both prevents HIV-1 infection in activated CD4 + T cells but also limits viral replication in CD4 + T cells that are already infected.
Elevation of Gal-9 in plasma of chronically HIV-1 infected individuals
Plasma Gal-9 concentrations in HIV+ individuals were measured by ELISA. We observed a significant increase (P < 0.0001) in plasma Gal-9 levels in HIV-1
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From infected individuals with > 10,000 copies/ml viral load than those with < 10,000 copies/ml ( Figure 4A ). HIV-1 negative and healthy controls had very low to undetectable levels of Gal-9 in their plasma (data not shown). Although, the average concentration of plasma Gal-9 was <200 ng/ml, it could be detected at > 500 ng/ml in the plasma of some chronically infected individuals ( Figure 4A ). Gal-9, even at concentration of 0.25 μg/ml and MOI= 0.025, reduced the infection of activated CD4 + T cells by about 50% (Supplementary Figure 6) . This suggested that the Gal-9 concentrations we used in the previous experiments were physiologically relevant.
Upregulation of p21 in CD4 + T cells following stimulation with Gal-9
We have shown that Gal-9 reduces expression of HIV-1 co-receptors as a possible inhibitory barrier against HIV-1 infection (Figure 2) . Recently, the cyclindependent kinase inhibitor, p21 has been shown to be strongly upregulated in Quantitative RT-PCR confirmed that Gal-9 induced a 2-10 fold (an average of > 4 fold) increase in mRNA expression of CDKN1A in Gal-9 treated CD4 + T cells compared with non-treated controls (P=0.0005; Figure 4C ). In addition, we ). In addition, Gal-9 can stimulate innate immunity, playing a protective role in viral, bacterial and parasite infections 10, 17, 42 and effectively limits tumor progression 11, 12 . Here, for the first time, we report a novel function for Gal-9 via Tim-3 in regulating CD4 + T cell susceptibility to infection by HIV-1 in vitro. Multiple effects of Gal-9 have been reported in different in vitro and in vivo systems; whereas Gal-9 affects many cellular process, different effects result from specific binding interactions with different . Thus, the function of Gal-9 could be contextual and different depending on the microenvironment, and the physiologic concentration of Gal-9 in different microenvironments in vivo is not known.
Gal-9 upregulates p21 and reduces infection of CD4 + T cells to HIV-1
In the present study, we have found Gal-9 to be circulating at significantly higher levels in the serum of HIV-1 infected individuals with a viral load of more than 10,000 copies/ml as compared to those with less than 10,000 copies/ml and normal healthy controls. Although the source of Gal-9 needs to be determined, elevated levels of Gal-9 in chronically HIV-1 infected individuals suggest that it may play an important role in HIV-1 pathogenesis.
We found that interaction of Gal-9 with Tim-3 on CD4 + T cells significantly inhibited HIV-1 infection by both X4-and R5-tropic isolates. These suppressive To our knowledge, the data presented here are the first to show that Gal-9 is directly involved in reducing the susceptibility of activated CD4 + T cells to HIV-1 infection in vitro. Studies to investigate whether Gal-9 can be used as a microbicide in vivo and whether Gal-9 provides a unique molecular barrier to
HIV-1 infection in different stages of HIV-1 infection will be important. The use of
Gal-9 at the mucosal surfaces can provide additional benefits for microbicides:
since Gal-9 can be naturally found either in the cytoplasm or the extracellular matrix 50 we would anticipate limited adverse effects with its administration. In addition, since the effects of Gal-9 on HIV-1 infection of CD4+ T cells are not virus-specific, we would anticipate no problems related to drug resistance of HIV-1, which is a potential problem with using antiviral drugs as microbicides.
However, careful studies will need to be undertaken as Gal-9 is a potent suppressor of T cell activation. Thus, administering it as a microbicide may result in untoward suppression of protective anti-microbial T cell responses in the genital mucosa.
Mucosal tissues play important roles in the earliest phases of infection after
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